Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Ann Rheum Dis. 2014 Aug 20;74(12):2236–2243. doi: 10.1136/annrheumdis-2014-205799

Figure 3.

Figure 3

Rituximab decreases dermal myofibroblast activation in IgG4-related disease (IgG4-RD) affected tissue. Immunohistochemistry for α-smooth muscle actin stain on skin biopsies from a patient with cutaneous IgG4-RD involvement, before (A and B) and after (C and D) treatment with rituximab. The number of moderately to strongly positive brown pixels per square micrometer decreases after rituximab in the regions containing predominantly dermal fibroblasts (outlined in blue) (original magnification: A and C 10×, inserts 20×). The morphology of individual fibroblasts before and after treatment is depicted at a higher magnification (40×) in B and D.